PFE
HealthcarePfizer
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2008–2025(18yr)| Metric | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.3B | $50.0B | $67.8B | $67.4B | $59.0B | $51.6B | $49.6B | $48.9B | $52.8B | $52.5B | $53.6B | $51.8B | $41.7B | $81.3B | $100.3B | $58.5B | $63.6B | $62.6B | -1.6% |
| Gross Profit | $40.2B | $41.1B | $51.5B | $52.3B | $47.7B | $42.0B | $40.0B | $39.2B | $40.5B | $41.3B | $42.4B | $41.5B | $33.0B | $50.5B | $66.0B | $33.5B | $45.8B | $46.5B | +1.6% |
| Gross Margin | 83.2% | 82.2% | 76.0% | 77.6% | 80.8% | 81.4% | 80.7% | 80.3% | 76.7% | 78.6% | 79.0% | 80.3% | 79.1% | 62.1% | 65.8% | 57.3% | 71.9% | 74.3% | +2.4pp |
| Net Income | $8.1B | $8.6B | $8.3B | $10.0B | $14.6B | $22.0B | $9.1B | $7.0B | $7.2B | $21.3B | $11.2B | $16.3B | $9.6B | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B | -3.2% |
| Net Margin | 16.8% | 17.3% | 12.2% | 14.8% | 24.7% | 42.7% | 18.4% | 14.2% | 13.7% | 40.6% | 20.8% | 31.4% | 23.1% | 27.0% | 31.3% | 3.6% | 12.6% | 12.4% | -0.2pp |
| Free Cash Flow | $16.5B | $15.4B | $9.9B | $18.6B | $15.7B | $16.6B | $15.7B | $13.1B | $14.1B | $14.5B | $13.8B | $10.4B | $12.2B | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B | -7.7% |
| FCF Margin | 34.2% | 30.8% | 14.7% | 27.6% | 26.7% | 32.1% | 31.6% | 26.8% | 26.7% | 27.6% | 25.7% | 20.1% | 29.2% | 36.7% | 25.9% | 8.2% | 15.5% | 14.5% | -1.0pp |
| EPS (Diluted) | $1.20 | $1.23 | $1.02 | $1.27 | $1.94 | $3.19 | $1.42 | $1.11 | $1.17 | $3.52 | $1.87 | $2.87 | $1.71 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 | -3.5% |
1. THE BIG PICTURE
Pfizer is a company in the midst of a violent transition, racing to replace a collapsing COVID-19 franchise with a new generation of "growth drivers" before its legacy blockbusters lose patent protection. While the headline revenue is shrinking, the underlying business is bifurcated: a non-COVID portfolio growing at 9% is currently being masked by a 70% operational decline in products like Paxlovid (8-K).
2. WHERE THE RISKS HIT HARDEST
- Innovation and R&D Strategy is threatened by Revenue Concentration because the multi-billion-dollar pipeline must successfully replace 12 products that currently account for 65% of total revenue but face patent expirations starting in 2026 (10-K Item 1, Risks).
- Value Demonstration is threatened by Pricing and Managed Care Pressures because government-mandated price cuts under the Inflation Reduction Act specifically target high-expenditure drugs like Eliquis, which alone accounts for 13% of Pfizer’s total sales (10-K Item 1, Risks).
- Business Development goals are threatened by Balance Sheet Constraints, as the $56.1 billion net debt load—resulting in 5.3x net leverage—limits Pfizer's ability to pursue further "key transactions" to bolster the post-2028 growth outlook (XBRL, CAPM analysis).
3. WHAT THE NUMBERS SAY TOGETHER
The combined data reveals a company with high-quality manufacturing—evidenced by a 74.4% gross margin—that is struggling with operational efficiency. Pfizer’s FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin of 17.0% is the lowest among its major peers, trailing leaders like Amgen (29.5%) and Merck (29.2%) by a wide margin (Peer Benchmarking). This suggests that while Pfizer is effective at making drugs, the costs of its "simplified structure" and massive R&DR&DResearch & Development — spending on creating new products or technologies engine are consuming a larger share of cash than its competitors.
The TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue decline of 1.6% is primarily a result of the COVID-19 product cycle mean-reverting. Excluding the 35% and 70% drops in Comirnaty and Paxlovid, the core portfolio’s 9% operational growth indicates that the underlying biopharmaceutical business remains structurally sound (8-K). However, the $1.6 billion net loss in the most recent quarter highlights the volatility of this transition (8-K). Short interest at 2.6% of the float suggests that while the market is skeptical, there is no significant speculative bet on a further collapse (Supplemental Signals).
4. IS IT WORTH IT AT THIS PRICE?
At 9.6x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Pfizer is attractively valued, trading at a 41% discount to the peer median of 16.1x (Peer Benchmarking). The market is currently pricing in a long-term growth rate of just 0.5% (CAPM analysis). This low bar suggests that if Pfizer can simply maintain its non-COVID growth trajectory and successfully launch its "20 key pivotal studies," the stock is significantly mispriced.
However, the discount is justified by the risk profile. Pfizer is the slowest grower in its peer group and carries the highest dividend yield at 6.4%, functioning more like a distressed utility than a high-growth biotech (Peer Benchmarking). For this price to be "right," the market must assume that the 2026–2030 patent expirations will result in a permanent contraction of the business that AI and new R&DR&DResearch & Development — spending on creating new products or technologies milestones cannot offset.
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if the non-COVID portfolio maintains operational growth above 8% while net debt begins to trend downward from the current $56.1 billion.
- Cautious if any of the "20 key pivotal study starts" mentioned by management face regulatory delays or fail to meet primary endpoints (8-K).
- Cautious if the net margin, which compressed by 0.2 percentage points recently, continues to decline, potentially threatening the 6.4% dividend yield (XBRL, Peer Benchmarking).
6. BOTTOM LINE
Structural Advantage: A massive global R&DR&DResearch & Development — spending on creating new products or technologies and manufacturing scale that currently supports a 74.4% gross margin and a non-COVID portfolio growing at nearly double digits. Bottom Line: Pfizer is a high-yield turnaround story where the valuation discount is deep enough to compensate for the looming patent cliff.
1. Top 5 Material Risks
- Revenue Concentration: 12 products accounted for 65% of total 2025 revenues, with Eliquis alone representing 13%. The loss of patent protection or regulatory exclusivity for these products—expected to accelerate between 2026 and 2030—poses a material threat to future revenue.
- Pricing and Managed Care Pressures: Private payors and PBMs are increasingly using utilization management tools, rebates, and formulary exclusions to control costs. These entities are consolidating, which increases their negotiating power to demand larger rebates or favor lower-cost generic alternatives over Pfizer’s branded medicines.
- Competitive Product Launches: Pfizer faces intense global competition, including from manufacturers in China with expanded R&DR&DResearch & Development — spending on creating new products or technologies capabilities. Competitors may offer superior efficacy, better safety profiles, or lower prices, which can erode market share and lead to product obsolescence.
- R&D and Pipeline Uncertainty: The discovery and development process is costly and unpredictable. Product candidates can fail at any stage, and Pfizer may fail to allocate R&DR&DResearch & Development — spending on creating new products or technologies resources efficiently, potentially leading to an inability to replenish product lines as older drugs lose exclusivity.
- Global Operational and Geopolitical Risks: With 41% of 2025 revenues derived from international operations (including 21% from Europe and 12% from China, Japan, and the rest of Asia Pacific), Pfizer is exposed to currency fluctuations, trade tensions, and government-mandated price controls in foreign markets.
2. Company-Specific Risks
- COVID-19 Product Volatility: Revenues from Comirnaty and Paxlovid have decreased substantially and remain subject to fluctuations based on infection trends, the timing of variant-adapted vaccine development, and changes in government recommendations for patient populations.
- Business Development Integration: Acquisitions such as Seagen and Metsera require substantial investment and debt financing. Failure to successfully integrate these businesses or realize anticipated synergies could lead to asset impairments and reduced financial flexibility.
- Counterfeit Threats: Pfizer’s high-demand medicines and vaccines are prime targets for counterfeiters. The proliferation of rogue online pharmacies and e-commerce scams threatens patient safety and could damage the Pfizer brand, leading to lost sales and potential litigation.
- Climate Change and Sustainability: Pfizer faces physical risks to its manufacturing facilities from extreme weather and transitional risks related to decarbonization goals. Failure to meet voluntary Net-Zero targets by 2040 could result in reputational damage and increased compliance costs.
3. Regulatory/Legal Risks
- IRA Price Setting: The Medicare Drug Price Negotiation Program (MDPNP) has already selected Eliquis, Ibrance, Xtandi, and Xeljanz for "Maximum Fair Price" setting, which directly impacts revenue.
- Manufacturing Compliance: Regulatory agencies periodically inspect facilities for cGMP compliance. Failures can lead to warning letters, suspension of manufacturing, or product recalls, such as the 2021 recall of Chantix due to nitrosamine levels.
- Legal Proceedings: Pfizer is involved in various patent, product liability, and government investigations. Adverse outcomes in patent litigation could result in the loss of exclusivity, while government investigations could lead to substantial fines, corporate integrity agreements, or limitations on business operations.
- Healthcare Reform: The OBBBA (July 2025) includes significant funding cuts to Medicaid and Medicare, which may lead to increased pricing controls and lower demand for Pfizer products.
4. Financial Impact Map
Revenue Concentration → Total Revenues → 65% of 2025 revenues derived from 12 products; 13% from Eliquis alone. IRA Price Controls → Total Revenues → Mandatory price setting for Eliquis (effective 2026), Ibrance and Xtandi (effective 2027), and Xeljanz (effective 2028). International Operations → Total Revenues → 41% of 2025 revenues derived from international markets, including 21% from Europe and 12% from China, Japan, and the rest of Asia Pacific. Business Development Debt → Long-term Debt → Proceeds from long-term debt issuance used to finance acquisitions of Seagen and Metsera. Intangible Asset Impairment → Intangible Assets and Goodwill → Significant amounts of IPR&D and goodwill on the balance sheet are subject to impairment if R&DR&DResearch & Development — spending on creating new products or technologies efforts are abandoned or reporting units underperform.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Mar 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Pfizer Q1 revenue $14.5B beats estimates, adjusted EPS $0.75 tops consensus
- ▸Q1 revenue $14.5B, exceeding $13.84B estimate
- ▸Adjusted EPS $0.75, beating consensus of $0.72
- ▸Non-COVID product revenue grew 7% operationally
- ▸Newer product portfolio delivered 22% operational growth YoY
- ▸Reaffirmed FY26 revenue guidance of $59.5B–$62.5B
Pfizer Q1 revenue $14.5B beats estimates, EPS $0.75 tops consensus
- ▸Q1 revenue $14.5B, +5% YoY, beating $13.84B estimate
- ▸Adjusted EPS $0.75, exceeding $0.72 consensus estimate
- ▸Revenue from launched and acquired products +22% operationally
- ▸Comirnaty revenue -59% and Paxlovid -63% operationally
- ▸Reaffirmed FY2026 revenue guidance of $59.5B–$62.5B and EPS $2.80–$3.00
Pfizer Q1 Earnings Beat Estimates, Reaffirms 2026 Growth Guidance
- ▸Q1 earnings topped analyst expectations
- ▸Reaffirmed 2026 financial guidance
- ▸Facing pressure to demonstrate growth beyond Covid-19 product portfolio
- ▸Managing $17 billion patent cliff impact on future revenue
Pfizer Lyme disease vaccine shows 73.2% efficacy in late-stage study
- ▸Lyme disease vaccine candidate showed 73.2% efficacy after fourth dose
- ▸Study missed key statistical reliability requirement due to low infection rates
- ▸Partners plan to proceed with regulatory submissions despite statistical shortfall
- ▸Valneva estimates peak annual sales of $1 billion for the vaccine
- ▸No currently approved vaccine exists for Lyme disease prevention
Pfizer Phase 3 Lyme vaccine and oncology trials meet key efficacy endpoints
- ▸Lyme disease vaccine achieved ~75% efficacy in Phase 3 trial
- ▸TALZENNA and atirmociclib met key endpoints in late-stage cancer studies
- ▸TALAPRO 3 Phase 3 trial success reinforces prostate cancer franchise
- ▸Projected 2028 revenue $59.6B and earnings $12.8B
- ▸Pipeline progress aims to offset patent expirations and revenue headwinds
Pfizer FY2025 dividend payout exceeds free cash flow by $695 million
- ▸FY2025 dividend payout of $9.771B exceeded free cash flow of $9.076B
- ▸GAAP payout ratio exceeds 100% based on $1.36 TTM EPS vs $1.72 dividend
- ▸Total debt increased to $67.4B in 2025 from $63.6B in 2024
- ▸Liquid assets declined to $13.6B from $20.5B year-over-year
- ▸FY2026 adjusted EPS guidance set at $2.80–$3.00
Pfizer reports new clinical data supporting expanded use of Talzenna in prostate cancer
- ▸New clinical data supports Talzenna use in earlier lines of prostate cancer care
- ▸Talzenna acquired by Pfizer as part of $14 billion deal
- ▸Current Talzenna sales described as negligible by market analysts
- ▸PARP inhibitor drug targeting specific prostate cancer patient populations
- ▸Data intended to broaden market adoption for existing oncology asset
Valneva FY2025 Revenue Exceeds €170M, Operating Loss €82.1M Amid R&D Spending
- ▸Total revenue exceeded €170M, slightly above 2024 levels
- ▸Operating loss of €82.1M vs prior year profit
- ▸Product sales decreased 3.3% due to third-party reductions and currency impacts
- ▸Operating cash burn reduced by over 20% via disciplined management
- ▸R&D expenses rose to €85.3M driven by Shigella and chikungunya programs
IP Group NAV per share rises 13% to £1.10 on Pfizer-linked obesity drug royalty
- ▸NAV per share increased 13% YoY to £1.10
- ▸Recognized £128M fair value for obesity drug royalty interest
- ▸Royalty interest stems from Pfizer's acquisition of Metsera
- ▸Portfolio focus remains on deep tech, clean tech, and life sciences
- ▸NAV growth driven by portfolio realizations and share buybacks
Olema Oncology ends 2025 with $505.4M cash; OPERA-01 data expected fall 2026
- ▸Cash, equivalents, and marketable securities totaled $505.4M at year-end 2025
- ▸Raised $218.5M gross proceeds from follow-on public offering in November 2025
- ▸Top-line data for Phase 3 OPERA-01 trial expected in fall 2026
- ▸Initiated Phase 1b/2 study of palazestrant with Pfizer's atirmociclib
- ▸Initial clinical data for OP-3136 expected in Q2 2026